ClinicalTrials.gg
TerminatedNCT03638466Updated May 2, 2025Results posted

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

A Phase 2 interventional study of Functional Magnetic Resonance Imaging (fMRI) and Magnetic Resonance Spectroscopy (MRS) in Attention Deficit Hyperactivity Disorder (ADHD) and Impulsive Aggression, sponsored by Supernus Pharmaceuticals, Inc.. Terminated at 3 sites in United States. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Basic science

Why this study was terminated
Financial decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
8 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Supernus Pharmaceuticals, Inc..

Enrollment
20th of 22
7 · median 192
Started
2019
with 2 others
Phase 2
5 of 22
none open now
Registered
16th of 22
by date

Among the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., this one is the 20th largest by enrollment, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 16th registered.

Attention Deficit Disorder with Hyperactivity

1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 8 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA). This was achieved using functional magnetic resonance imaging (fMRI) in conjunction with the point subtraction aggression paradigm (PSAP) Task, a behavioral aggression paradigm in which subjects are provoked by having money indirectly taken from them by a fictitious opponent, simulating an aggression response.

Read the detailed description

Approximately 30 subjects aged 8-12 diagnosed with ADHD and associated feature of IA were recruited in this study. The PSAP is a behavioral aggression test used to evaluate behavioral response related to impulsive aggression. The task was combined with functional MRI to evaluate the change in brain activity measured as BOLD signal (blood oxygenation level-dependent) from baseline to the end of the treatment with SPN-810.

The level of neurotransmitters Glutamate and GABA were also measured using magnetic resonance spectroscopy (MRS).

Additionally, the improvement and severity in impulsive aggression behaviors were assessed using validated scales.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Impulsive Aggression
04

Who can participate

Ages eligible
8 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Otherwise healthy male or female subjects, aged 8-12 years, inclusive, at the time of screening with primary diagnosis of ADHD and currently receiving monotherapy treatment with an optimized US Food and Drug Administration (FDA)-approved ADHD medication.
  • Impulsive aggression (IA) confirmed at screening using the R-MOAS and the Vitiello Aggression Scale.

Exclusion criteria

Exclusion Criteria:

  • Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar disorder, schizophrenia or related disorder, personality disorder, Tourette's disorder, fetal alcohol syndrome, or psychosis not otherwise specified.
  • Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorder.
  • Known or suspected IQ \<70, pregnancy, substance or alcohol abuse.
  • Known history of implanted brain stimulator, vagal nerve stimulator, ventriculoperitoneal shunt, cardiac pacemaker, orthodontic braces, or implanted medication port. Visual and hearing (≥25 dB) impairment.
  • Pre-existing medical or psychological conditions that preclude being in the MRI scanner (e.g., claustrophobia, morbid obesity, or marked anxiety about the procedure).
05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Active comparator
    High dose SPN-810 (36 mg)

    Subjects were randomized to receive SPN-810 18 mg twice a day twice each day with and without food, in addition to the stable dose of the optimized ADHD medication.

    Diagnostic Test: Functional Magnetic Resonance Imaging (fMRI) · Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) · Behavioral: Point Subtraction Aggression Paradigm (PSAP) Task · Drug: SPN-810

  • Placebo comparator
    Placebo

    Subjects were randomized to receive Placebo twice a day twice each day with and without food, in addition to the stable dose of the optimized ADHD medication.

    Diagnostic Test: Functional Magnetic Resonance Imaging (fMRI) · Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) · Behavioral: Point Subtraction Aggression Paradigm (PSAP) Task · Drug: Placebo

Interventions

  • Diagnostic testFunctional Magnetic Resonance Imaging (fMRI)

    Neural brain activity measured by fMRI

  • Diagnostic testMagnetic Resonance Spectroscopy (MRS)

    Glutamate and GABA levels measured by MRS

  • BehavioralPoint Subtraction Aggression Paradigm (PSAP) Task

    Aggression score measured by the PSAP task

  • Treatment of SPN-810 (36 mg) on neuronal brain activity, GABA and Glutamate levels and on the aggression score

  • DrugPlacebo

    Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score

06

What researchers measure

Primary outcomes

  1. Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task

    The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response.

    Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

  2. Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task

    BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response.

    Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

  3. Effect of SPN-810 on the Aggressions Score

    The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the "aggression" action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression.

    Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

Secondary outcomes

  1. Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)

    GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5.

    Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

Other outcomes

  1. Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale

    The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35).

    Time frame: From Visit 1 (Day -30) to two time points: Visit 4 (Day 21) and Visit 6 (Day 35).

  2. Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale

    The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse.

    Time frame: Visit 4 (Day 21) and Visit 6 (Day 35), for a total of 2 weeks.

  3. Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score

    R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit.

    Time frame: Visit 1 (Day -30) to Visit 4 (Day 21) and Visit 6 (Day 35).

07

Results

Posted May 2, 2025

Participant flow

A multi-center, double-blind, randomized (1:1), placebo-controlled, parallel-group, 2-arm study

Participant flow — Overall Study
MilestonePlaceboHigh Dose SPN-810 (36 mg)
Started43
Randomized population43
Completed population42
Completed42
Not completed01
Withdrew: Early termination01

Outcome measures

PrimaryAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task

The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response.

Time frame:
Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Reported as:
Mean · Voxels
Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task
VoxelsSPN-810 (36 mg) > PlaceboPlacebo > SPN-810 (36 mg)
Inferior Occipital Gyrus/Cerebellum: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5353 (310.6 to 395.4)0 (0 to 0)
Right Fusiform Gyrus/Inferior Occipital Cortex: Montreal Neurological Institute 32.5, 52.5, 23.5258 (223.1 to 292.9)0 (0 to 0)
Left Angular Gyrus (WM): Montreal Neurological Institute coordinates 4.5, 84.5, 35.5173 (145.2 to 200.8)0 (0 to 0)
Left Cuneus: Montreal Neurological Institute coordinates -23.5, 96.5, 5.5145 (124.6 to 165.4)0 (0 to 0)
Right Middle Occipital Gyrus: Montreal Neurological Institute coordinates -1.5, 64.5, 57.5133 (114.2 to 151.8)0 (0 to 0)
Medial Precuneus: Montreal Neurological Institute coordinates -33.5, 34.5, 47.5128 (111.3 to 144.7)0 (0 to 0)
Right Postcentral Gyrus: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5110 (95.1 to 124.9)0 (0 to 0)
Superior Medial Frontal Gyrus: Montreal Neurological Institute coordinates 2.5, -47.5, 39.50 (0 to 0)329 (288.6 to 369.4)
Right Cerebellum: Montreal Neurological Institute coordinates: -35.5, 72.5, -40.50 (0 to 0)175 (145.2 to 204.8)
Right Superior/Middle Frontal Gyrus: Montreal Neurological Institute coordinates -37.5, -33.5, 33.50 (0 to 0)164 (136.2 to 191.8)
Right Insula Montreal Neurological Institute coordinates -39.5, -13.5, -0.50 (0 to 0)140 (116.4 to 163.6)
Right Inferior Temporal Gyrus: Montreal Neurological Institute coordinates -41.5, -7.5, -46.50 (0 to 0)145 (124.6 to 165.4)
Left Postcentral Gyrus: Montreal Neurological Institute coordinates 30.5, 30.5, 51.50 (0 to 0)110 (95.1 to 124.9)
PrimaryProvocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task

BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response.

Time frame:
Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Reported as:
Mean · Voxels
Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task
VoxelsSPN-810 (36 mg) > PlaceboPlacebo > SPN-810 (36 mg)
Right Postcentral Gyrus: Montreal Neurological Institute coordinates: -31.5, 30.5, 43.5318 (276.3 to 359.7)0 (0 to 0)
Left Middle/Inferior Temporal Gyrus: Montreal Neurological Institute coordinates 52.5, 16.5, -24.5137 (117.5 to 156.5)0 (0 to 0)
Medial Cerebellum: Montreal Neurological Institute coordinates: 12.5, 50.5 -32.50 (0 to 0)123 (104.1 to 141.9)
Left Inferior Frontal Gyrus: Montreal Neurological Institute coordinates: 42.5, -15.5, 19.50 (0 to 0)122 (105.0 to 139.0)
Right Cerebellum: Montreal Neurological Institute coordinates: -23.5, 70.5, -24.50 (0 to 0)109 (94.4 to 123.6)
PrimaryEffect of SPN-810 on the Aggressions Score

The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the "aggression" action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression.

Time frame:
Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Reported as:
Mean · score on a scale
Effect of SPN-810 on the Aggressions Score
score on a scalePlaceboHigh Dose SPN-810 (36 mg)
Baseline/Visit 28.43 ± 9.2210.23 ± 6.21
Visit 59.26 ± 5.504.02 ± 2.60
SecondaryEffect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)

GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5.

Time frame:
Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Reported as:
Mean · mM
Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)
mMPlaceboHigh Dose of SPN-810 (36 mg)
GABA (mM)0.79 ± 0.260.75 ± 0.67
Glutamate (mM)0.78 ± 2.440.23 ± 1.91
Other pre-specifiedEffect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale

The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35).

Time frame:
From Visit 1 (Day -30) to two time points: Visit 4 (Day 21) and Visit 6 (Day 35).
Reported as:
Mean · score on a scale
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale
score on a scalePlaceboHigh Dose SPN-810
Visit 4-1.25 ± 1.5-1.5 ± 2.12
Visit 6-2.25 ± 1.5-1.5 ± 2.12
Other pre-specifiedEffect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale

The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse.

Time frame:
Visit 4 (Day 21) and Visit 6 (Day 35), for a total of 2 weeks.
Reported as:
Mean · score on a scale
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale
score on a scalePlaceboHigh Dose of SPN-810 (36 mg)
Visit 42.3 ± 1.261.5 ± 0.71
Visit 62.3 ± 1.261.0 ± 0.0
Other pre-specifiedEffect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score

R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit.

Time frame:
Visit 1 (Day -30) to Visit 4 (Day 21) and Visit 6 (Day 35).
Reported as:
Mean · score on a scale
Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score
score on a scalePlaceboHigh Dose SPN-810 (36 mg)
Visit 4-52.0 ± 30.23-43.0 ± 2.83
Visit 6-61.0 ± 18.81-39.5 ± 24.75

Adverse events

Collected over Visit 3 (Day 1) to Visit 6 (Week5)-End of Study, a total of 5 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/4 (0%)0/4 (0%)2/4 (50%)
High Dose SPN-8100/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent other events
Most frequent other events
EventPlaceboHigh Dose SPN-810
Decrease appetiteMetabolism and nutrition disorders2/40/3
Blood Prolactin IncreasedInvestigations0/41/3
FatigueGeneral disorders1/40/3

Baseline characteristics

Randomized Population: The Randomized Population consists of all enrolled subjects who completed the Baseline Period including imaging scans, meet the inclusion/exclusion criteria and were randomized to SPN-810 36 mg or Placebo.

Age, Categorical
Age, Categorical(Participants)PlaceboHigh Dose SPN-810 (36 mg)Total
<=18 years437
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)PlaceboHigh Dose SPN-810 (36 mg)Total
Mean9.5 ± 1.2911.3 ± 1.1510.3 ± 1.50
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboHigh Dose SPN-810 (36 mg)Total
Female022
Male415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboHigh Dose SPN-810 (36 mg)Total
Hispanic or Latino224
Not Hispanic or Latino213
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboHigh Dose SPN-810 (36 mg)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White213
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)PlaceboHigh Dose SPN-810 (36 mg)Total
United States437
Vitiello Aggression Total Score
Vitiello Aggression Total Score(units on a scale)PlaceboHigh Dose SPN-810 (36 mg)Total
Mean-3.5 ± 1.29-3.7 ± 1.53-3.6 ± 1.27
Retrospective-Modified Overt Aggression Scale (R-MOAS) Total Score
Retrospective-Modified Overt Aggression Scale (R-MOAS) Total Score(units on a scale)PlaceboHigh Dose SPN-810 (36 mg)Total
Mean102.5 ± 32.3057.0 ± 6.0083.0 ± 33.54

1 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Meridien Research aka Florida Clinical Research Center, LLC
    Lakeland, Florida 33805, United States
  • Florida Clinical Research Center, LLC.
    Maitland, Florida 32751, United States
  • University of South Florida- Dept. of Psychiatry and Neurosciences
    Tampa, Florida 33613, United States
09

References and documents

Publications

  • Cherek DR, Moeller FG, Schnapp W, Dougherty DM. Studies of violent and nonviolent male parolees: I. Laboratory and psychometric measurements of aggression. Biol Psychiatry. 1997 Mar 1;41(5):514-22. doi: 10.1016/s0006-3223(96)00059-5. PubMed 9046983 ↗
  • Bubenzer-Busch S, Herpertz-Dahlmann B, Kuzmanovic B, Gaber TJ, Helmbold K, Ullisch MG, Baurmann D, Eickhoff SB, Fink GR, Zepf FD. Neural correlates of reactive aggression in children with attention-deficit/hyperactivity disorder and comorbid disruptive behaviour disorders. Acta Psychiatr Scand. 2016 Apr;133(4):310-23. doi: 10.1111/acps.12475. Epub 2015 Aug 21. PubMed 26292852 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Nov 2019, 5 months.

Results were first posted in May 2025, 5 years 5 months after primary completion. A results delay was requested in Jan 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Aug 20, 2018
StartActual
May 30, 2019
Primary completionActual
Nov 7, 2019
CompletionActual
Nov 7, 2019
Results delay requested
Jan 12, 2021
Results first posted
May 2, 2025
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03638466
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
May 30, 2019
Primary completion
Nov 7, 2019
Completion
Nov 7, 2019
Results posted
May 2, 2025
Last update
May 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molindone

Start the discussion